America's Enduring Supply-Chain Vulnerabilities to China: Rare Earths, Pharma, and Electronics Expose National Security Risks

Recent developments underscore persistent U.S. dependence on China for critical materials, echoing warnings from 2020 COVID-era threats and extending into 2025-2026 trade tensions. China controls approximately 70% of global rare earth mining and over 90% of processing and refining capacity, enabling export restrictions in retaliation for U.S. tariffs and blacklisting actions.[1][2][3] In April 2025, Beijing restricted rare earth and magnet exports, disrupting defense and industrial supply chains; while some easing occurred later, U.S. imports remained suppressed compared to pre-restriction levels.[4] Heavy rare earths, vital for magnets in military systems, EVs, and chips, show near-total Chinese dominance at 99% for certain elements.[5]

Similar patterns appear in pharmaceuticals. China supplies key starting materials (KSMs) for a substantial portion of generic active pharmaceutical ingredients (APIs), with estimates of sole-sourcing for 41% of certain inputs and control over 80%+ in key segments like antibiotics and precursors for drugs such as amoxicillin (94% of KSMs).[6][7] This creates chokepoints where disruptions could cascade through Indian finishing stages to U.S. markets.

In electronics, China leads printed circuit board (PCB) production and exports, holding dominant shares in Asia-Pacific manufacturing hubs critical for semiconductors, defense hardware, and consumer devices.[8][9] Broader analyses highlight private-sector incentives sustaining engagement despite policy pushes for diversification, with U.S. firms citing market size and resilience in 2026 surveys.[10]

Experts frame this as a national security imperative requiring coordinated action beyond market forces, as seen in ongoing efforts to build domestic capacity that face decade-long timelines.[11]